Macarena Hernández
Associate Professor, Complutense University & Chief Scientific Officer AptaTargets
Seminars
Wednesday 22nd April 2026
Panel Discussion: Differentiating Next-Gen Oligonucleotides for CNS Therapeutics Safety, Stability & Competitive Advantage
8:30 am
- Discussing safety profiles, stability and translational outcomes across different oligo subtypes including ASO’s, siRNA, saRNA, aptamers and more
- Comparative safety and toxicity considerations across subtypes including off target effects, immunogenicity and long-term durability
- Industry perspective on room for innovation and strategies to stand out in a crowded therapeutic landscape
- What differentiates next-generation modalities and how biopharma can differentiate themselves in an increasingly competitive space
Wednesday 22nd April 2026
Clinical Translation of CNS Aptamer Therapeutics: From Bench to Bedside
9:00 am
- Explore the discovery and validation process steps in developing aptamer-based therapeutics for CNS applications
- Overview of AptaTargets clinical development pathway, including preclinical research as well as Phase I and Phase II clinical trials
- Considering the future direction of Phase III clinical development and the continued advancement of CNS aptamer therapeutics
